Several previous studies reported that treatment with an SGLT2 inhibitor for 1–12 weeks significantly increased fasting or postprandial plasma glucagon levels in type 2 diabetes patients [13–15]. Here, SLC5A2 is linked to type 2 diabetes mellitus.